Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency

Introduction

The use of medicines is one of the challenges posed by human activities to environmental sustainability¹. After consumption, medicines are released into the environment through excretion in urine and feces, either unchanged or as inactivated or still as active metabolites. Additionally, they can be released directly in wastewater in the case of topically applied formulations or improper disposal of medications through toilets. This enables medicines to enter wastewater and, subsequently, surface waters, potentially causing adverse effects on the fauna and flora in these environments¹. The exposure of aquatic organisms to medicines can result in various adverse reactions that threaten the ecosystem. For example, exposure to hormonal agents may lead to the feminization of male fish, certain analgesics can induce nephrotoxicity in various animal species, and the presence of antibiotics can contribute to the development of resistance in animals, plants, and humans^2–4.

At the European level, measures have been undertaken to assess the presence and environmental risk associated with medicines. These measures have concentrated explicitly on monitoring surface waters, as they represent the first environment affected by the consequences of human medicine use. Since 2006 the European Medicines Agency (EMA) has required pharmaceutical manufacturers to include an Environmental Risk Assessment (ERA) as part of the European Public Assessment Report (EPAR) during the marketing authorization process for a pharmaceutical product. The ERA should provide information on the toxicity of the active pharmaceutical ingredients to aquatic organisms, along with details on the risk based on expected consumption⁵. Furthermore, in 2008 the European Commission (EC) introduced a compulsory monitoring system for surface water aimed at tracking a group of chemical substances, known as Watch List, which may pose harm to the environment. The monitoring campaign began in 2015, periodically reviewing the list of monitored substances, which include also human medicines⁶. In March 2019, the European Commission presented the “Strategic Approach to Pharmaceuticals in the Environment”, which includes actions aimed at countering the negative effects of medicines on the environment throughout their entire lifecycle, from design and production to use and disposal⁷.

However, the task of monitoring medicines in surface waters is a resource-intensive endeavor that is often limited to a specific set of substances. Therefore, it is essential to prioritize the substances for monitoring by employing estimation methods that go beyond the pre-marketing estimates supplied by manufacturers seeking marketing authorization from the EMA. A commonly adopted measure for estimating the environmental impact of medicines is the Risk Quotient (RQ), calculated as the ratio between the Predicted Environmental Concentration (PEC) and the Predicted No-Effect Concentration (PNEC)⁵. The PNEC represents a tolerability threshold for organisms exposed to the medicines derived from in-vivo tests⁸, while the PEC can be estimated in-silico using various approaches. Currently, calculating the PEC commonly relies on the method proposed by the Swedish Association of Pharmaceutical Industries (Lif - Läkemedelsindustriföreningen), which adapts the EMA’s approach for post-marketing scenarios^9,10. Lif has incorporated an environmental risk section on the FASS (Farmacevtiska specialiteter i Sverige) website (www.fass.se) as part of this approach, providing information on each pharmaceutical product supplied in Sweden. Building on this initiative, the Region Stockholm has developed a dedicated web-based database for disseminating environmental information on medicines, including those found in FASS and other documents^11,12. Inspired by the Swedish example, the Finnish Pharmaceutical Information Centre (Pharmaca) has integrated environmental information on medicines into the Pharmaca Fennica online service^13,14. Other countries, such as Norway and Italy, have contributed to the development of their country-specific environmental risk assessments for medicines through publications in the scientific literature^15,16.

The Italian Medicines Agency (AIFA – Agenzia Italiana del Farmaco) recently joined this initiative to map the environmental impact of medicines. In its 2022 annual OsMed report on national drug utilization (English version released in December 2023), a section was dedicated to estimate the environmental risk in Italy based on drug utilization data¹⁷.

This study aimed at assessing environmental risks of medicines used in Italy at the national, macro-area, and regional levels.

Methods

Results

A total of 90 medicines were identified based on our selection criteria and thus included in this analysis for environmental risk assessment (see Table S2). The majority of medicines belonged to cardiovascular agents (ATC C, n=21), anti-infectives for systemic use (ATC J, 16), and antineoplastic and immunomodulating agents (ATC L, 14). Six medicines, namely allopurinol, diclofenac, estradiol, ethinylestradiol, levonorgestrel, and metformin, were selected based on more than one criterion.

At the Italian level, 13 medicines were identified as posing a high risk to surface waters (see Figure 1 and Table S3). Among them, two cardiovascular agents (ATC C, olmesartan and lacidipine) and four antibiotics (ATC J, rifaximin, ofloxacin, azithromycin, and amoxicillin). Other substances at high risk included the estrogen estradiol (ATC G), two nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and diclofenac (ATC M), two antidepressants—venlafaxine and sertraline (ATC N), the ectoparasiticide permethrin and the antiprotozoal atovaquone (ATC P). Furthermore, 23 medicines were categorized as having a moderate risk. The remaining 54 medicines were identified to have a low or insignificant risk according to assessments at the Italian level (see Figure 1 and Table S3).

• Download figure
• Open in new tab

Figure 1

Risk level for the 90 selected medicines in Italy in 2022

The high risk stemmed from a very low PNEC for permethrin, estradiol, lacidipine, and atovaquone. Although permethrin and atovaquone are not frequently used, their high dose per quantity (2.25 grams) contributed to the risk profile. In contrast, estradiol and lacidipine are more commonly used, albeit with a lower quantity per dose. Conversely, other medicines at high risk, namely amoxicillin, azithromycin, ofloxacin, diclofenac, and ibuprofen have high PNEC values, but their widespread use and the high quantity per dose exacerbated their risk (see Table S3).

The analysis of the environmental risk at the macro-area level showed that risk was influenced by drug utilization patterns. Specifically, the high risk associated with lacidipine, ofloxacin, and azithromycin was driven by elevated consumption in the central and southern regions. Atovaquone’s high risk was uniquely influenced by the elevated consumption observed in Central Italy. Other notable patterns included the high risk of levonorgestrel restricted to Northern Italy, and the high risk of clotrimazole, clindamycin, ciprofloxacin, imatinib, montelukast, and ebastine restricted to Central Italy. Conversely, miconazole exhibited a high risk in both Central and Southern Italy (see Figure 2). These patterns are reflective of the distinctive drug utilization patterns within individual regions and the subsequent local environmental risks (see Figure S1).

• Download figure
• Open in new tab

Figure 2

Risk level of the 90 selected medicines in 2022 divided by Italian macro-area

Discussion

To our knowledge, this is the first study investigating the environmental impact of an extended range of medicines in Italy, starting from drug utilization data. We identified different high-risk medications, including NSAIDs, hormonal agents, antidepressants, cardiovascular drugs, and antibiotics.

The majority of therapeutic classes considered in this analysis exhibited at least one medicine posing either a high or moderate level of risk. This suggested that the environmental risk was widespread and distributed across various types of medicines. Notably, the only classes that did not show any risk in this analysis were the ATC B class of blood agents and the ATC S class of sensory organs agents. However, it’s important to acknowledge that the number of medicines from these classes included in the assessment was relatively limited and that most sensory agents have also another ATC code.

Commonly used medicines posing a high risk to Italian surface waters were the NSAIDs such as diclofenac and ibuprofen. The environmental impact of diclofenac has widely been studied and it is recognized to cause severe environmental damage^28,29, with a high risk being acknowledged in different countries³⁰. On the other hand, ibuprofen, despite its high risk, driven essentially by wide consumption, may have an overall lower environmental impact because it had a lower potential for bioaccumulation and persistence^30,31. Otherwise, ketoprofen, acetylsalicylic acid, and paracetamol, belonging to the same therapeutic area, showed a low risk. Despite their similarly high consumption, their PNEC values were higher compared to those of diclofenac and ibuprofen, resulting in a lower environmental risk.

Hormonal agents commonly employed for contraceptive purposes, and to lesser extent for menopausal symptom treatment, were associated with either a high or moderate level of risk. These substances are widely acknowledged for their potential to cause harm when present in surface water because of their capability to disrupt the hormonal equilibrium of different aquatic species. For example, they can cause the feminization of male fish and consequently disrupt ecological equilibrium². Contraceptives represented a striking example of medicines with low opportunity to reduce the uses to limit the environmental impact. Rather, the only measure to limit it would be to improve wastewater treatment systems.

Another pharmaceutical compound identified as posing a high risk to the environment is permethrin, an antiparasitic agent commonly employed for the treatment and prevention of head lice and scabies³². Since permethrin is extensively utilized in agriculture as a broad-spectrum insecticide, the hazard to the environment is probably even higher^33,34. Also, the antiprotozoal atovaquone has been identified as posing a high environmental risk. While these latter two medicines have been identified as potential high-risk emerging contaminants on the basis of PNEC values obtained in experimental conditions, their effects on real aquatic ecosystems have not been thoroughly studied^35–37.

The antidepressants sertraline and venlafaxine, respectively a selective serotonin reuptake inhibitor (SSRI) and a serotonin-norepinephrine reuptake inhibitor (SNRI), were identified as posing a high environmental risk. They are widely used to treat a broad spectrum of prevalent psychiatric disorders, including major depression and anxiety disorders³⁸. The primary toxic effect observed in exposed fish was alteration in behavior, although there are conflicting findings^39–42. Clinical alternatives, such as citalopram and escitalopram, have higher PNEC²², potentially rendering their environmental risk lower.

Among the ATC class C medicines, olmesartan, an angiotensin II receptor blocker⁴³, and lacidipine, a calcium channel blocker also used for hypertension⁴⁴, were estimated to pose a high environmental risk. In contrast, the angiotensin II receptor blocker, valsartan, resulted in an insignificant impact on the environment. Among the calcium channel blockers class, felodipine presented a moderate risk, while amlodipine and nisoldipine presented a low risk. Moreover, ramipril, an ACE inhibitor, was estimated to pose a moderate risk, while the beta-blockers bisoprolol, nebivolol, and propranolol resulted in a low or insignificant environmental risk. Certain studies emphasized that medicines within the same therapeutic class may exhibit distinct behaviors during wastewater treatment. For instance, among angiotensin II receptor blockers, olmesartan degrades more slowly than valsartan, adding complexity to their risk assessment⁴⁵. A few studies have identified adverse reactions, including reproductive problems and issues related to biochemistry, such as disturbances in lipid metabolism, oxidative stress, and steroid levels⁴⁶, but, overall, the effects of cardiovascular agents on aquatic organisms and plants remained insufficiently explored. Given the vast array of medicines available for the treatment of hypertension and the large number of people affected, it is crucial to consider the environmental impact in the overall assessment of these medications even at the moment of medical prescription. This should be included in a comprehensive assessment of their sustainability, along with their clinical risk-benefits, costs, and accessibility to patients.

Finally, a high environmental risk was estimated for certain antibacterials and antibiotics. The penicillin amoxicillin, the macrolide azithromycin, and the fluoroquinolone ofloxacin were identified as high-risk medicines. Rifaximin, an antibiotic mainly used to treat traveler’s diarrhea caused by Escherichia Coli, was also classified as high-risk. However, it is important to note that it could be purchased in Italy for use during travels abroad. Additionally, this medicine may be overused for the treatment of certain diseases, such as diverticulitis⁴⁷. Moderate risk was estimated for ciprofloxacin (a fluoroquinolone) and clarithromycin (a macrolide), while erythromycin, another macrolide, was estimated at low risk. The elevated risk associated with commonly used antibacterials in Italy raised significant concerns, particularly regarding potential adverse impacts on aquatic flora and fauna⁴⁸. Beyond posing immediate threats to the aquatic environment, these antibacterials also exhibit a worrisome capacity for bioaccumulation, further amplifying the risk. Moreover, the potential for the development of antibiotic-resistant strains adds a critical layer to the potential consequences, emphasizing the need for careful monitoring and management of antibiotic use to safeguard both environmental and public health^4,49,50. Similarly, to cardiovascular drug classes, the environmental impact of each antimicrobial agent should be added to the clinical profile to provide physicians with additional information to make the appropriate therapeutic choice.

We identified some differences in the environmental risk of certain medicines across Italian regions. These differences reflected local drug prescription attitudes and consumption patterns and may reflect different healthcare practices and socio-economic disparities. Regions with higher consumption rates of high-risk medicines may benefit from targeted initiatives aimed at both physicians and patients, promoting responsible drug prescription practices, raising awareness about the environmental consequences of improper drug disposal and implementation of advanced wastewater treatment systems.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Author contribution

VG, MF, EP, CL, AC, FF, and SZ conceptualized and designed the study. VG, MF, CL, EP, AC, FF, SZ, AP curated drug utilization data. VG retrieved data other than drug utilization, and performed analyses and graphical visualization. VG wrote the original draft. MF, CL, EP, AC, FF, SZ revised and integrated the original draft. All the authors read and approved the final version.